Abarelix (Plenaxis™): A Gonadotropin-Releasing Hormone Antagonist for Medical Castration in Patients with Advanced Prostate Cancer

Clinical Prostate Cancer

Volumn 2, Issue 4, 2004, Pages 209-211

  Reddy, G Kesava ^a   Jain, Vinay K ^a   Sartor, Oliver ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; FOLLITROPIN; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; GONADORELIN; OLIGOPEPTIDE;

ADVANCED CANCER; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; FATIGUE; FOLLITROPIN BLOOD LEVEL; GYNECOMASTIA; HEADACHE; HOT FLUSH; HUMAN; HYPOTENSION; LUTEINIZING HORMONE BLOOD LEVEL; ORCHIECTOMY; PAIN; PERIPHERAL EDEMA; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SLEEP DISORDER; SYNCOPE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; URTICARIA; DRUG ANTAGONISM; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

CLINICAL TRIALS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM METASTASIS; OLIGOPEPTIDES; PROSTATIC NEOPLASMS;

EID: 2942600189     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70046-4     Document Type: Article

References (8)

1. Chrisp P, Sorkin EM. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1991; 1:487-509.
2. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144:1479-1480.
3. Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165:1585-1589.
4. Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000; 5:162-168.
5. Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol 2000; 4:275-277.
6. Plenaxis [package insert]. Waltham, MA: Praecis Pharmaceuticals Inc., 2003.
7. McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58:756-761.
8. Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167:1670-1674.